7 research outputs found
Induction and decay of functional complement-fixing antibodies by the RTS,S malaria vaccine in children, and a negative impact of malaria exposure
Background: Leading malaria vaccine, RTS,S, is based on the circumsporozoite protein (CSP) of sporozoites. RTS,S
confers partial protection against malaria in children, but efficacy wanes relatively quickly after primary
immunization. Vaccine efficacy has some association with anti-CSP IgG; however, it is unclear how these antibodies
function, and how functional antibodies are induced and maintained over time. Recent studies identified antibodycomplement interactions as a potentially important immune mechanism against sporozoites. Here, we investigated
whether RTS,S vaccine-induced antibodies could function by interacting with complement.
Methods: Serum samples were selected from children in a phase IIb trial of RTS,S/AS02A conducted at two study
sites of high and low malaria transmission intensity in Manhiça, Mozambique. Samples following primary
immunization and 5-year post-immunization follow-up time points were included. Vaccine-induced antibodies were
characterized by isotype, subclass, and epitope specificity, and tested for the ability to fix and activate complement.
We additionally developed statistical methods to model the decay and determinants of functional antibodies after
vaccination.
Results: RTS,S vaccination induced anti-CSP antibodies that were mostly IgG1, with some IgG3, IgG2, and IgM.
Complement-fixing antibodies were effectively induced by vaccination, and targeted the central repeat and Cterminal regions of CSP. Higher levels of complement-fixing antibodies were associated with IgG that equally
recognized both the central repeat and C-terminal regions of CSP. Older age and higher malaria exposure were
significantly associated with a poorer induction of functional antibodies. There was a marked decay in functional
complement-fixing antibodies within months after vaccination, as well as decays in IgG subclasses and IgM.
Statistical modeling suggested the decay in complement-fixing antibodies was mostly attributed to the waning of
anti-CSP IgG1, and to a lesser extent IgG3. Conclusions: We demonstrate for the first time that RTS,S can induce complement-fixing antibodies in young
malaria-exposed children. The short-lived nature of functional responses mirrors the declining vaccine efficacy of
RTS,S over time. The negative influence of age and malaria exposure on functional antibodies has implications for
understanding vaccine efficacy in different settings. These findings provide insights into the mechanisms and
longevity of vaccine-induced immunity that will help inform the future development of highly efficacious and longlasting malaria vaccines
Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
Joining a function-enhanced Fc-portion of human IgG to the SARS-CoV-2 entry receptor ACE2 produces an antiviral decoy with strain transcending virus neutralizing activity. SARS-CoV-2 neutralization and Fc-effector functions of ACE2-Fc decoy proteins, formatted with or without the ACE2 collectrin domain, were optimized by Fc-modification. The different Fc-modifications resulted in distinct effects on neutralization and effector functions. H429Y, a point mutation outside the binding sites for FcγRs or complement caused non-covalent oligomerization of the ACE2-Fc decoy proteins, abrogated FcγR interaction and enhanced SARS-CoV-2 neutralization. Another Fc mutation, H429F did not improve virus neutralization but resulted in increased C5b-C9 fixation and transformed ACE2-Fc to a potent mediator of complement-dependent cytotoxicity (CDC) against SARS-CoV-2 spike (S) expressing cells. Furthermore, modification of the Fc-glycan enhanced cell activation via FcγRIIIa. These different immune profiles demonstrate the capacity of Fc-based agents to be engineered to optimize different mechanisms of protection for SARS-CoV-2 and potentially other viral pathogens
Induction and decay of functional complement-fixing antibodies by the RTS,S malaria vaccine in children, and a negative impact of malaria exposure
Background: Leading malaria vaccine, RTS,S, is based on the circumsporozoite protein (CSP) of sporozoites. RTS,S
confers partial protection against malaria in children, but efficacy wanes relatively quickly after primary
immunization. Vaccine efficacy has some association with anti-CSP IgG; however, it is unclear how these antibodies
function, and how functional antibodies are induced and maintained over time. Recent studies identified antibodycomplement interactions as a potentially important immune mechanism against sporozoites. Here, we investigated
whether RTS,S vaccine-induced antibodies could function by interacting with complement.
Methods: Serum samples were selected from children in a phase IIb trial of RTS,S/AS02A conducted at two study
sites of high and low malaria transmission intensity in Manhiça, Mozambique. Samples following primary
immunization and 5-year post-immunization follow-up time points were included. Vaccine-induced antibodies were
characterized by isotype, subclass, and epitope specificity, and tested for the ability to fix and activate complement.
We additionally developed statistical methods to model the decay and determinants of functional antibodies after
vaccination.
Results: RTS,S vaccination induced anti-CSP antibodies that were mostly IgG1, with some IgG3, IgG2, and IgM.
Complement-fixing antibodies were effectively induced by vaccination, and targeted the central repeat and Cterminal regions of CSP. Higher levels of complement-fixing antibodies were associated with IgG that equally
recognized both the central repeat and C-terminal regions of CSP. Older age and higher malaria exposure were
significantly associated with a poorer induction of functional antibodies. There was a marked decay in functional
complement-fixing antibodies within months after vaccination, as well as decays in IgG subclasses and IgM.
Statistical modeling suggested the decay in complement-fixing antibodies was mostly attributed to the waning of
anti-CSP IgG1, and to a lesser extent IgG3. Conclusions: We demonstrate for the first time that RTS,S can induce complement-fixing antibodies in young
malaria-exposed children. The short-lived nature of functional responses mirrors the declining vaccine efficacy of
RTS,S over time. The negative influence of age and malaria exposure on functional antibodies has implications for
understanding vaccine efficacy in different settings. These findings provide insights into the mechanisms and
longevity of vaccine-induced immunity that will help inform the future development of highly efficacious and longlasting malaria vaccines
The Complement System Contributes to Functional Antibody Mediated Responses Induced by Immunization with Plasmodium falciparum Malaria Sporozoites
Contains fulltext :
193054.pdf (publisher's version ) (Open Access
Additional file 1: of Human antibodies activate complement against Plasmodium falciparum sporozoites, and are associated with protection against malaria in children
Supplementary figures: Supporting data. (DOCX 1232Â kb
Human antibodies activate complement against Plasmodium falciparum sporozoites, and are associated with protection against malaria in children
BACKGROUND: Antibodies targeting Plasmodium falciparum sporozoites play a key role in human immunity to malaria. However, antibody mechanisms that neutralize sporozoites are poorly understood. This has been a major constraint in developing highly efficacious vaccines, as we lack strong correlates of protective immunity. METHODS: We quantified the ability of human antibodies from malaria-exposed populations to interact with human complement, examined the functional effects of complement activity against P. falciparum sporozoites in vitro, and identified targets of functional antibodies. In children and adults from malaria-endemic regions, we determined the acquisition of complement-fixing antibodies to sporozoites and their relationship with antibody isotypes and subclasses. We also investigated associations with protective immunity in a longitudinal cohort of children (n = 206) residing in a malaria-endemic region. RESULTS: We found that antibodies to the major sporozoite surface antigen, circumsporozoite protein (CSP), were predominately IgG1, IgG3, and IgM, and could interact with complement through recruitment of C1q and activation of the classical pathway. The central repeat region of CSP, included in leading vaccines, was a key target of complement-fixing antibodies. We show that antibodies activate human complement on P. falciparum sporozoites, which consequently inhibited hepatocyte cell traversal that is essential for establishing liver-stage infection, and led to sporozoite death in vitro. The natural acquisition of complement-fixing antibodies in malaria-exposed populations was age-dependent, and was acquired more slowly to sporozoite antigens than to merozoite antigens. In a longitudinal cohort of children, high levels of complement-fixing antibodies were significantly associated with protection against clinical malaria. CONCLUSIONS: These novel findings point to complement activation by antibodies as an important mechanism of anti-sporozoite human immunity, thereby enabling new strategies for developing highly efficacious malaria vaccines. We also present evidence that complement-fixing antibodies may be a valuable correlate of protective immunity in humans